Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study

Archives of Pediatrics and Adolescent Medicine

Volumn 163, Issue 11, 2009, Pages 978-985

  Crider, Krista S ^a   Cleves, Mario A ^b   Reefhuis, Jennita ^a   Berry, Robert J ^a   Hobbs, Charlotte A ^b   Hu, Dale J ^a  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEPHALOSPORIN; ERYTHROMYCIN; NITROFURANTOIN; PENICILLIN G; QUINOLONE DERIVATIVE;

ADULT; AORTA COARCTATION; ARTICLE; BIRTH DEFECT; CHOANA ATRESIA; CONTROLLED STUDY; FEMALE; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; NEWBORN; PREGNANCY; PRIORITY JOURNAL; RISK FACTOR;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; ANENCEPHALY; ANOPHTHALMOS; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CEPHALOSPORINS; CHOANAL ATRESIA; CLEFT LIP; CLEFT PALATE; ERYTHROMYCIN; FEMALE; HEART DEFECTS, CONGENITAL; HERNIA, DIAPHRAGMATIC; HUMANS; LIMB DEFORMITIES, CONGENITAL; MICROPHTHALMOS; MIDDLE AGED; NITROFURANTOIN; PENICILLINS; POPULATION SURVEILLANCE; PREGNANCY; QUINOLONES; SULFONAMIDES; TETRACYCLINES; UNITED STATES; YOUNG ADULT;

EID: 70350741361     PISSN: 10724710     EISSN: 15383628     Source Type: Journal    
DOI: 10.1001/archpediatrics.2009.188     Document Type: Article

References (14)

1. Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004;191(2):398-407.
2. Czeizel AE, Rockenbauer M, Olsen J. Use of antibiotics during pregnancy. Eur J Obstet Gynecol Reprod Biol. 1998;81(1):1-8.
3. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002.
4. Yoon PW, Rasmussen SA, Lynberg MC, et al. The National Birth Defects Prevention Study. Public Health Rep. 2001;116(suppl 1):32-40. (Pubitemid 32822091)
5. Werler MM, Sheehan JE, Mitchell AA. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol. 2002;155(1):26-31.
6. US Food and Drug Administration. United States FDA pharmaceutical pregnancy categories. Fed Regist. 1980;44:37434-37467.
7. Cogswell ME, Bitsko RH, Anderka M, et al. Control selection and participation in an ongoing, population-based, case-control study of birth defects: the National Birth Defects Prevention Study. Am J Epidemiol. In press.
8. Niebyl JR. Antibiotics and other anti-infective agents in pregnancy and lactation. Am J Perinatol. 2003;20(8):405-414.
9. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. Nitrofurantoin and congenital abnormalities. Eur J Obstet Gynecol Reprod Biol. 2001;95(1):119-126.
10. Nahum GG, Uhl K, Kennedy DL. Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gynecol. 2006;107(5):1120-1138. (Pubitemid 43755551)
11. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. The teratogenic risk of trimethoprim- sulfonamides: a population based case-control study. Reprod Toxicol. 2001;15(6):637-646. (Pubitemid 34000933)
12. Czeizel AE, Puho E, Sorensen HT, Olsen J. Possible association between different congenital abnormalities and use of different sulfonamides during pregnancy. Congenit Anom (Kyoto). 2004;44(2):79-86.
13. Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000;343(22):1608-1614. (Pubitemid 32162984)
14. Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol. 2001;153(10):961-968. (Pubitemid 32423782)